Azitra, with $3.8m cash, advances ATR-04 trial and widens rash population

Azitra has told investors that its ATR-04 trial can proceed to the next dose group, while the company's balance sheet remains small. In its third-quarter 2026 results, published on 12 November, the US company reported a net loss of $3.0 million and cash of $3.8 million at the end of the period.

ATR-04 is a live biotherapeutic being developed for skin rash caused by cancer treatment. Azitra said the independent committee overseeing safety in the Phase 1/2 study had recommended moving from Cohort 1 to Cohort 2. The company did not provide details of trial size or dosing in the material reviewed by CompePharma.

The study's eligibility criteria now cover rash associated with KRAS and MEK inhibitors, including cases in patients with neurofibromatosis type 1. That enlarges the pool of patients the trial can recruit from beyond its original design. Azitra gave no figures for the size of that population or for any commercial opportunity.

Two readouts are due by the end of 2026. Topline data from Cohort 1 are expected in the fourth quarter, and results for ATR-COSF, the company's cosmetic ingredient programme, are also guided for year-end. The Cohort 1 data would be the first public clinical results for ATR-04.

The cash figure sits only modestly above the quarter's net loss, though net loss is not the same as cash burn and Azitra's summary offered no runway guidance. How far the balance sheet can carry the programme past these readouts is therefore not clear from the disclosures.